However, a recent study showed that Rheb activity was reduced in striatal tissues of patients with HD and mice with HD, and that activation of mammalian target of rapamycin complex 1 (mTORC1) by introducing caRheb, a constitutively active form, could mitigate the metabolic and degenerative phenotypes in striatal tissues of mice with HD [37]. The gene discussed is RHEB; the disease is Huntington disease.